Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVX ABIVAX Société Anonyme	$7.02 -5.4%	$6.50	$4.77 ▼ $14.22	$445.32M	0.01	150,908 shs	97,905 shs
ATYR Atyr PHARMA	$5.43 +0.7%	$3.65	$1.42 ▼ $5.98	$483.29M	0.88	1.04 million shs	1.37 million shs
HURA TuHURA Biosciences	$2.62 -1.5%	$3.62	$1.80 ▼ $7.93	$114.44M	0.23	235,350 shs	78,114 shs
ZVRA Zevra Therapeutics	$9.37 -0.1%	$7.92	$4.20 ▼ $9.76	$512.35M	2.01	664,348 shs	480,071 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVX ABIVAX Société Anonyme	-5.72%	-7.94%	+15.94%	+25.34%	-47.34%
ATYR Atyr PHARMA	-2.00%	+4.86%	+66.36%	+35.09%	+538,999,900.00%
HURA TuHURA Biosciences	-2.21%	-5.67%	-30.37%	+34.34%	+265,999,900.00%
ZVRA Zevra Therapeutics	+1.08%	+4.80%	+21.03%	+18.14%	+93.80%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABVX ABIVAX Société Anonyme	1.9885 of 5 stars	3.5	2.0	0.0	0.0	2.0	0.8	0.6
ATYR Atyr PHARMA	2.8449 of 5 stars	3.6	1.0	0.0	0.0	3.2	3.3	0.6
HURA TuHURA Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ZVRA Zevra Therapeutics	2.8992 of 5 stars	3.6	2.0	0.0	0.0	4.1	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABVX ABIVAX Société Anonyme	3.00	Buy	$31.00	341.60% Upside
ATYR Atyr PHARMA	3.14	Buy	$18.60	242.54% Upside
HURA TuHURA Biosciences	3.25	Buy	$12.67	383.46% Upside
ZVRA Zevra Therapeutics	3.11	Buy	$22.29	137.84% Upside

Current Analyst Ratings Breakdown

Latest HURA, ZVRA, ABVX, and ATYR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/4/2025	ATYR Atyr PHARMA	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$35.00
5/19/2025	ATYR Atyr PHARMA	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$35.00 ➝ $35.00
5/16/2025	HURA TuHURA Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00 ➝ $12.00
5/14/2025	ZVRA Zevra Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
5/14/2025	ZVRA Zevra Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$25.00 ➝ $25.00
4/30/2025	ABVX ABIVAX Société Anonyme	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$33.00 ➝ $33.00
4/3/2025	HURA TuHURA Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$13.00 ➝ $12.00
3/20/2025	ABVX ABIVAX Société Anonyme	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Equal Weight	$12.00
3/14/2025	ATYR Atyr PHARMA	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$35.00 ➝ $35.00
3/13/2025	ZVRA Zevra Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$23.00 ➝ $25.00
3/13/2025	ZVRA Zevra Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $22.00

(Data available from 6/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABVX ABIVAX Société Anonyme	N/A	N/A	N/A	N/A	$3.37 per share	N/A
ATYR Atyr PHARMA	$235K	2,056.56	N/A	N/A	$1.54 per share	3.53
HURA TuHURA Biosciences	N/A	N/A	N/A	N/A	($4.11) per share	N/A
ZVRA Zevra Therapeutics	$40.59M	12.62	N/A	N/A	$1.71 per share	5.48

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABVX ABIVAX Société Anonyme	-$159.90M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	8/11/2025 (Estimated)
ATYR Atyr PHARMA	-$50.39M	-$0.81	N/A	N/A	N/A	N/A	-79.44%	-59.16%	8/12/2025 (Estimated)
HURA TuHURA Biosciences	-$8.32M	N/A	0.00	∞	N/A	N/A	N/A	-152.88%	N/A
ZVRA Zevra Therapeutics	-$46.05M	-$1.90	N/A	46.85	N/A	-342.63%	-159.54%	-51.50%	8/12/2025 (Estimated)

Latest HURA, ZVRA, ABVX, and ATYR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	HURA TuHURA Biosciences	-$0.13	-$0.15	-$0.02	-$0.15	N/A	N/A
5/13/2025	Q1 2025	ZVRA Zevra Therapeutics	-$0.21	-$0.06	+$0.15	-$0.06	$16.96 million	$20.40 million
5/7/2025	Q1 2025	ATYR Atyr PHARMA	-$0.19	-$0.17	+$0.02	-$0.17	N/A	N/A
3/13/2025	Q4 2024	ATYR Atyr PHARMA	-$0.23	-$0.18	+$0.05	-$0.18	$0.02 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABVX ABIVAX Société Anonyme	N/A	N/A	N/A	N/A	N/A
ATYR Atyr PHARMA	N/A	N/A	N/A	N/A	N/A
HURA TuHURA Biosciences	N/A	N/A	N/A	N/A	N/A
ZVRA Zevra Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABVX ABIVAX Société Anonyme	0.48	3.04	N/A
ATYR Atyr PHARMA	0.02	5.41	5.41
HURA TuHURA Biosciences	N/A	1.54	1.54
ZVRA Zevra Therapeutics	0.84	2.88	2.88

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABVX ABIVAX Société Anonyme	47.91%
ATYR Atyr PHARMA	61.72%
HURA TuHURA Biosciences	0.62%
ZVRA Zevra Therapeutics	35.03%

Insider Ownership

Company	Insider Ownership
ABVX ABIVAX Société Anonyme	N/A
ATYR Atyr PHARMA	3.70%
HURA TuHURA Biosciences	0.20%
ZVRA Zevra Therapeutics	2.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABVX ABIVAX Société Anonyme	61	63.44 million	N/A	Not Optionable
ATYR Atyr PHARMA	53	89.00 million	80.84 million	Optionable
HURA TuHURA Biosciences	N/A	43.68 million	42.20 million	N/A
ZVRA Zevra Therapeutics	20	54.68 million	52.10 million	Optionable

HURA, ZVRA, ABVX, and ATYR Headlines

Recent News About These Companies

Cantor Fitzgerald Forecasts ZVRA FY2026 Earnings

June 12 at 1:45 AM | americanbankingnews.com

Cantor Fitzgerald Predicts ZVRA FY2026 Earnings

June 11 at 8:45 AM | marketbeat.com

Bank of America Corp DE Increases Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

June 9 at 3:07 AM | marketbeat.com

Nuveen Asset Management LLC Reduces Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

June 5, 2025 | marketbeat.com

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Shares Purchased by Millennium Management LLC

June 3, 2025 | marketbeat.com

Zevra Therapeutics: Zevra Announces Final Results of 2025 Annual Meeting of Stockholders

May 31, 2025 | finanznachrichten.de

Zevra Therapeutics Stockholders Re-Elect Wendy L. Dixon, Ph.D. and Tamara A. Favorito to Board of Directors Amid Commitment to Growth Strategy

May 31, 2025 | nasdaq.com

Zevra Announces Final Results of 2025 Annual Meeting of Stockholders

May 29, 2025 | globenewswire.com

Citizens JMP Reiterates Buy Rating on Zevra Therapeutics (ZVRA), Keeps PT

May 27, 2025 | insidermonkey.com

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Consensus Rating of "Buy" by Analysts

May 27, 2025 | marketbeat.com

Northern Trust Corp Buys 81,252 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

May 25, 2025 | marketbeat.com

Zevra Therapeutics (NASDAQ:ZVRA) Upgraded to Buy at Wall Street Zen

May 24, 2025 | marketbeat.com

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Shares Bought by Woodline Partners LP

May 23, 2025 | marketbeat.com

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) is Velan Capital Investment Management LP's 9th Largest Position

May 21, 2025 | marketbeat.com

All Three Leading Proxy Advisory Firms – ISS, Glass Lewis, and Egan-Jones – Recommend Zevra Stockholders Vote FOR the Company's Director Nominees

May 21, 2025 | globenewswire.com

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Stock Holdings Lowered by Stonepine Capital Management LLC

May 20, 2025 | marketbeat.com

Q2 EPS Forecast for Zevra Therapeutics Raised by Analyst

May 20, 2025 | marketbeat.com

Roth Capital Lifts Earnings Estimates for Zevra Therapeutics

May 18, 2025 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Flora Growth (FLGC), Cardinal Health (CAH) and Zevra Therapeutics (ZVRA)

May 16, 2025 | theglobeandmail.com

With 49% stake, Zevra Therapeutics, Inc. (NASDAQ:ZVRA) seems to have captured institutional investors' interest

May 15, 2025 | finance.yahoo.com

Zevra Reports First Quarter 2025 Financial Results and Corporate Update

May 14, 2025 | taiwannews.com.tw

New MarketBeat Followers Over Time

Media Sentiment Over Time

HURA, ZVRA, ABVX, and ATYR Company Descriptions

ABIVAX Société Anonyme NASDAQ:ABVX

$7.02 -0.40 (-5.39%)

As of 04:00 PM Eastern

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

Atyr PHARMA NASDAQ:ATYR

$5.43 +0.04 (+0.74%)

As of 04:00 PM Eastern

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

TuHURA Biosciences NASDAQ:HURA

$2.62 -0.04 (-1.50%)

As of 04:00 PM Eastern

TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.

Zevra Therapeutics NASDAQ:ZVRA

$9.37 -0.01 (-0.11%)

As of 04:00 PM Eastern

Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time